JP4087929B2 - Composition for treating chronic renal failure in cats and method for treating the same - Google Patents
Composition for treating chronic renal failure in cats and method for treating the same Download PDFInfo
- Publication number
- JP4087929B2 JP4087929B2 JP23086497A JP23086497A JP4087929B2 JP 4087929 B2 JP4087929 B2 JP 4087929B2 JP 23086497 A JP23086497 A JP 23086497A JP 23086497 A JP23086497 A JP 23086497A JP 4087929 B2 JP4087929 B2 JP 4087929B2
- Authority
- JP
- Japan
- Prior art keywords
- renal failure
- composition
- cats
- chronic renal
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は猫の慢性腎不全を安全かつ効果的に治療するための組成物及びこれを用いた治療方法に関する。
【０００２】
【従来の技術】
近年、ワクチンや予防薬の普及によりペットの寿命が延びた結果、猫においても高齢化が進捗しており、慢性腎不全は増加の傾向にある。
【０００３】
猫の慢性腎不全は腎臓の機能が慢性的に低下してしまったため、本来、腎臓から排泄されるべき老廃物が充分に排泄できなくなり、尿素窒素、クレアチニンなど尿毒症物質といわれる物質が体内に蓄積され沈鬱、食欲低下、などの異常を呈する疾患である。
【０００４】
猫は、犬や他の動物と異なり経口で飲料をあまり摂取しないという特性を有することから、その慢性腎不全に対する補液療法は、乳酸リンゲル補液等の投与を経静脈や皮下など非経口的な経路で実施せざるを得ない状況にあり、滅菌、保温などの煩雑さを伴うのに加え無菌操作、投与経路の確保など投与に熟練を必要とし、しかも、直接、体内に投与するため、前記補液の処方が適切でなかった場合の副作用の危険も大であった。更に、前記補液の投与を非経口的な経路で実施する場合には、入院又は通院して定期的に点滴を続ける必要があり飼い主の負担は大きなものがあった。
前記補液を経口で投与しても、やはり摂取量は少なく、経口による治療は難しいものであった。
【０００５】
【発明が解決しようとする課題】
従って、本発明の目的は慢性腎不全の猫に対し経口で投与できる安全かつ効果的な治療剤及び治療方法を提供することにある。
【０００６】
【課題を解決するための手段】
そこで本発明者は上記目的を達成すべく種々検討してきたところ、特定濃度のＮａ+及びＫ+を含有する水溶液又はエマルジョンを与えれば、全く意外にも慢性腎不全の猫がこれを積極的に経口で摂取し、かつ腎不全の症状が顕著に改善することを見出し、本発明を完成するに至った。
【０００７】
すなわち、本発明は、Ｎａ+を２０〜１５０mEq／ｌ及びＫ+を１０〜４０mEq／ｌ含有し、かつ両者の合計含有量が４０〜１９０mEq／ｌである水溶液又はエマルジョンからなる猫慢性腎不全治療用経口投与用組成物を提供するものである。
また、本発明は、Ｎａ+を２０〜１５０mEq／ｌ及びＫ+を１０〜４０mEq／ｌ含有し、かつ両者の合計含有量が４０〜１９０mEq／ｌとなる水溶液又はエマルジョンを経口投与することを特徴とする猫の慢性腎不全の治療方法を提供するものである。
【０００８】
【発明の実施の形態】
本発明の猫慢性腎不全治療用経口投与用組成物に含有されるＮａ+源としては、塩化ナトリウム、クエン酸ナトリウム、乳酸ナトリウム、炭酸ナトリウム、炭酸水素ナトリウム、リン酸ナトリウム、酢酸ナトリウム、硫酸ナトリウム、コハク酸ナトリウム、リンゴ酸ナトリウム、フマル酸ナトリウム、マレイン酸ナトリウム、グルコン酸ナトリウム、酒石酸ナトリウム等が挙げられる。またＫ+源としては、塩化カリウム、クエン酸カリウム、乳酸カリウム、炭酸カリウム、炭酸水素カリウム、リン酸カリウム、酢酸カリウム、硫酸カリウム、コハク酸カリウム、リンゴ酸カリウム、フマル酸カリウム、マレイン酸カリウム、グルコン酸カリウム、酒石酸カリウム等が挙げられる。
【０００９】
Ｎａ+は水溶液又はエマルジョンとしたとき２０〜１５０mEq／ｌとなる量を含有するが、特に猫の経口摂取性及び腎不全治療効果の点から４０〜１００mEq／ｌとなる量を含有するのがより好ましい。またＫ+は、水溶液又はエマルジョンとしたとき１０〜４０mEq／ｌとなる量を含有するが、特に猫の経口摂取性及び腎不全の治療効果の点から１０〜３０mEq／ｌとなる量含有するのがより好ましい。更に、両者の合計含有量は４０〜１９０mEq／ｌである。
【００１０】
また、本発明組成物には、上記成分以外にＣａ2+、Ｍｇ2+などのカチオンを有してもよい。これらのカチオンは、前記Ｎａ+源又はＫ+源として挙げられた対アニオンとの塩の形態で配合されるのが好ましい。
【００１１】
更に、本発明組成物には、ブドウ糖、蔗糖、デキストリン等の水溶性糖類；油脂、アミノ酸等を含有してもよい。
【００１２】
本発明組成物は、水溶液又はエマルジョンなどの形態で経口投与されるものであり、経口投与時の水溶液又はエマルジョンが上記の含有組成になればよい。
この水溶液又はエマルジョンの浸透圧は１００〜４５０mOsm／ｌが好ましく、またpHは、４．０〜８．５であることが好ましい。
【００１３】
通常猫はあまり水を摂取しないにもかかわらず、本発明の水溶液又はエマルジョンを慢性腎不全の猫に与えると、猫はこれを積極的に摂取するようになる。そして、慢性腎不全の典型的な血液生化学的所見である血液尿素窒素値（以下、「ＢＵＮ」という）及びクレアチニン値が顕著に改善され、また体内水分量及びカリウム量も顕著に改善される。更に、臨床的所見として、元気及び食欲も回復し、体重も回復する。
【００１４】
本発明組成物は、前記のように水溶液又はエマルジョンの形態で慢性腎不全の猫に自由摂取させればよく、投与量は特に制限されないが、猫１頭あたり、５０〜１０００ml／日投与することが好ましく、症状の改善を観察しながら与えればよい。
【００１５】
【実施例】
次に実施例を挙げて本発明を詳細に説明するが、本発明はこれに何ら制限されるものではない。
【００１６】
実施例１
慢性腎不全と診断された猫（日本猫、雄）に、表１の処方の組成物（本発明品Ａ）６ｇを２００mlの水に溶かして１週間自由摂取させた。投与開始時及び投与１週間後に血液の生化学検査を行った。
【００１７】
【表１】
その結果、試験開始時のクレアチニン値は５．１mg／dlであったが、投与１週間後は２．９mg／dlに低下した。また、試験開始時のＢＵＮは７６mg／dlであったが、投与１週間後は４４mg／dlに低下した。
【００１９】
また給与１週間後には、低下していたカリウム値も正常に近い値に回復した。更に、飲水量（本発明組成物を含む）が明らかに増加し、症状的にも元気がでてきた。
【００２０】
実施例２
慢性腎不全と診断された猫（日本猫、雄）に、本発明品Ａ６ｇ、表２の処方の組成物（本発明品Ｂ１０．８６８ｇ、及びＣ１．１０２ｇ、並びに比較品ａ１０ｇ及びｂ３ｇ）をそれぞれ２００mlの水に溶かして１〜２週間自由摂取させた。投与開始時及び投与１週間後に血液の生化学検査を行った。
【００２１】
【表２】
その結果、本発明品Ａ、Ｂ及びＣを投与して１週間後には１０．１mg／dlであったクレアチニン値がそれぞれ、７．７mg／dl、７．９mg／dl、７．４mg／dlに低下し、ＢＵＮ値も９６mg／dlからそれぞれ９０mg／dl、６８mg／dl、８５mg／dlに低下した。一方、比較品ａ及びｂを投与した場合には、クレアチニン及びＢＵＮともにほとんど低下しなかった。また、本発明品Ａ、Ｂ及びＣを投与すると飲水量が投与前１９６ml／dayからそれぞれ３６８ml／day、３６１ml／day、４１２ml／dayと増加した。また、ペットフードの摂取量も増加した。
【００２３】
【発明の効果】
本発明の組成物は経口投与であるので従来の点滴などによる方法と比べ家庭においても簡便に猫の慢性腎不全の治療が実施できる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a composition for safely and effectively treating chronic renal failure in cats and a treatment method using the same.
[0002]
[Prior art]
In recent years, the life expectancy of pets has increased due to the spread of vaccines and preventive drugs. As a result, cats are aging and chronic renal failure is increasing.
[0003]
In chronic kidney failure in cats, the function of the kidney has been chronically reduced, so that waste products that should be excreted from the kidney cannot be excreted sufficiently, and substances called uremic substances such as urea nitrogen and creatinine are in the body. It is a disease that accumulates and causes abnormalities such as depression and loss of appetite.
[0004]
Unlike cats and other animals, cats have the property that they do not take much drink orally. Therefore, fluid replacement therapy for chronic renal failure is the use of parenteral routes such as intravenous and subcutaneous administration of lactate Ringer's fluid replacement. In addition to the complexity of sterilization and heat retention, it requires skill in administration such as aseptic operation and securing the administration route. The risk of side effects when the prescription was not appropriate was also great. Furthermore, when the administration of the replacement fluid is performed by a parenteral route, it is necessary to continue infusions regularly after hospitalization or hospitalization, and there is a great burden on the owner.
Even if the replacement fluid was administered orally, the amount of intake was still small, and oral treatment was difficult.
[0005]
[Problems to be solved by the invention]
Accordingly, an object of the present invention is to provide a safe and effective therapeutic agent and method that can be administered orally to cats with chronic renal failure.
[0006]
[Means for Solving the Problems]
Therefore, the present inventor has made various studies to achieve the above object, and if an aqueous solution or emulsion containing a specific concentration of Na + and K + is given, a cat with chronic renal failure will be able to do this. It was taken orally and the symptoms of renal failure were found to be remarkably improved, and the present invention was completed.
[0007]
That is, the present invention is, N a a 20~150mEq / l and K + a + containing 10~40mEq / l, and feline chronic renal failure total content of both of an aqueous solution or emulsion is 40~190mEq / l A therapeutic composition for oral administration is provided.
Further, the present invention is characterized by orally administering an aqueous solution or emulsion containing 20 to 150 mEq / l of Na + and 10 to 40 mEq / l of K + and a total content of both of 40 to 190 mEq / l. The present invention provides a method for treating chronic renal failure in cats.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the Na + source contained in the composition for oral administration for the treatment of cat chronic renal failure according to the present invention include sodium chloride, sodium citrate, sodium lactate, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium acetate, sodium sulfate. Sodium succinate, sodium malate, sodium fumarate, sodium maleate, sodium gluconate, sodium tartrate and the like. Examples of K + sources include potassium chloride, potassium citrate, potassium lactate, potassium carbonate, potassium hydrogen carbonate, potassium phosphate, potassium acetate, potassium sulfate, potassium succinate, potassium malate, potassium fumarate, potassium maleate, Examples include potassium gluconate and potassium tartrate.
[0009]
Na + contains 20 to 150 mEq / l of an aqueous solution or emulsion, but more preferably contains 40 to 100 mEq / l in view of the oral intake of cats and the effect of treating renal failure. preferable. K + contains 10-40 mEq / l of an aqueous solution or emulsion, especially 10-30 mEq / l in view of the oral intake of cats and the therapeutic effect of renal failure. Is more preferable. Furthermore, the total content of both is 40 to 190 mEq / l.
[0010]
In addition to the above components, the composition of the present invention may have cations such as Ca 2+ and Mg 2+ . These cations are preferably formulated in the form of a salt with the counter anion mentioned as the Na + source or K + source.
[0011]
Furthermore, the composition of the present invention may contain water-soluble saccharides such as glucose, sucrose and dextrin; fats and oils, amino acids and the like.
[0012]
The composition of the present invention is orally administered in the form of an aqueous solution or an emulsion, and the aqueous solution or emulsion at the time of oral administration only needs to have the above-described composition.
The osmotic pressure of this aqueous solution or emulsion is preferably 100 to 450 mOsm / l, and the pH is preferably 4.0 to 8.5.
[0013]
Although cats usually do not consume much water, when they are given an aqueous solution or emulsion according to the present invention to cats with chronic renal failure, they will actively take it. In addition, blood urea nitrogen level (hereinafter referred to as “BUN”) and creatinine level, which are typical blood biochemical findings of chronic renal failure, are significantly improved, and body water content and potassium level are also significantly improved. . Furthermore, as clinical findings, energy and appetite are restored, and weight is also restored.
[0014]
The composition of the present invention may be freely ingested by a cat with chronic renal failure in the form of an aqueous solution or emulsion as described above, and the dose is not particularly limited, but 50 to 1000 ml / day is administered per cat. It is preferable to give it while observing improvement in symptoms.
[0015]
【Example】
EXAMPLES Next, although an Example is given and this invention is demonstrated in detail, this invention is not restrict | limited at all to this.
[0016]
Example 1
A cat diagnosed with chronic renal failure (Japanese cat, male) was allowed to ingest 6 g of the composition (invention A) according to the formulation shown in Table 1 in 200 ml of water and freely ingested for 1 week. Blood biochemistry was performed at the start of administration and one week after administration.
[0017]
[Table 1]
As a result, the creatinine value at the start of the test was 5.1 mg / dl, but decreased to 2.9 mg / dl one week after administration. The BUN at the start of the test was 76 mg / dl, but decreased to 44 mg / dl one week after administration.
[0019]
In addition, one week after the salary, the decreased potassium level recovered to a value close to normal. Furthermore, the amount of drinking water (including the composition of the present invention) was clearly increased, and the symptom was fine.
[0020]
Example 2
For cats (Japanese cats and males) diagnosed with chronic renal failure, the product A6g of the present invention, the compositions of the formulations in Table 2 (the products B10.868g and C1.102g of the present invention, and comparative products a10g and b3g), respectively. It was dissolved in 200 ml of water and allowed to take freely for 1-2 weeks. Blood biochemistry was performed at the start of administration and one week after administration.
[0021]
[Table 2]
As a result, the creatinine values which were 10.1 mg / dl one week after administration of the products A, B and C of the present invention were 7.7 mg / dl, 7.9 mg / dl and 7.4 mg / dl, respectively. The BUN value also decreased from 96 mg / dl to 90 mg / dl, 68 mg / dl and 85 mg / dl, respectively. On the other hand, when comparative products a and b were administered, both creatinine and BUN hardly decreased. Also, when the products A, B and C of the present invention were administered, the amount of drinking water increased from 196 ml / day before administration to 368 ml / day, 361 ml / day and 412 ml / day, respectively. Pet food intake has also increased.
[0023]
【The invention's effect】
Since the composition of the present invention is orally administered, cats can be easily treated for chronic renal failure in cats at home as compared with conventional infusion methods.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23086497A JP4087929B2 (en) | 1997-08-27 | 1997-08-27 | Composition for treating chronic renal failure in cats and method for treating the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23086497A JP4087929B2 (en) | 1997-08-27 | 1997-08-27 | Composition for treating chronic renal failure in cats and method for treating the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH1171287A JPH1171287A (en) | 1999-03-16 |
| JPH1171287A5 JPH1171287A5 (en) | 2005-03-10 |
| JP4087929B2 true JP4087929B2 (en) | 2008-05-21 |
Family
ID=16914509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23086497A Expired - Lifetime JP4087929B2 (en) | 1997-08-27 | 1997-08-27 | Composition for treating chronic renal failure in cats and method for treating the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4087929B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI813560B (en) * | 2017-04-18 | 2023-09-01 | 國立大學法人東北大學 | Pharmacologically blood cleaning by alkalizing agent |
| TWI847827B (en) * | 2017-04-18 | 2024-07-01 | 國立大學法人東北大學 | Pharmacologically blood cleaning by alkalizing agent |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7578234B2 (en) * | 2017-04-18 | 2024-11-06 | 国立大学法人東北大学 | Alkalizing agents for blood purification |
-
1997
- 1997-08-27 JP JP23086497A patent/JP4087929B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI813560B (en) * | 2017-04-18 | 2023-09-01 | 國立大學法人東北大學 | Pharmacologically blood cleaning by alkalizing agent |
| TWI847827B (en) * | 2017-04-18 | 2024-07-01 | 國立大學法人東北大學 | Pharmacologically blood cleaning by alkalizing agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1171287A (en) | 1999-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Doré et al. | Comparison of oral, intravenous, and subcutaneous fluid therapy for resuscitation of calves with diarrhea | |
| US20040105895A1 (en) | Monovalent-selective cation exchangers as oral sorbent therapy | |
| JP3933702B2 (en) | Composition for mineral supplementation after gastrectomy | |
| Jacobsen et al. | Methanol and formate kinetics in late diagnosed methanol intoxication | |
| CN102099042B (en) | Single (iron hydroxypyrone) and combined (iron hydroxypyrone and inhibitor of gastrointestinal inflammation) compositions for anemia or helicobacter pylori infection | |
| IE59057B1 (en) | Veterinary compositions | |
| US5164192A (en) | Effervescent composition for oral rehydration | |
| JP4638106B2 (en) | Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solution for pharmaceutical use | |
| US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
| KR20170104575A (en) | A carboxylic acid mixture for treating patients with kidney failure | |
| JP2011225609A (en) | Use of alpha-ketoglutaric acid for treatment of malnutrition or high plasma glucose condition | |
| JP3676362B2 (en) | Improved peritoneal dialysis fluid containing polypeptides. | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| JP4087929B2 (en) | Composition for treating chronic renal failure in cats and method for treating the same | |
| US3928578A (en) | Composition for control of white muscle disease | |
| Michell | Oral rehydration for diarrhoea: symptomatic treatment or fundamental therapy | |
| Davies | Paraquat poisoning: the rationale for current treatment regimes | |
| AU651824B2 (en) | Pharmaceutical composition | |
| HU229185B1 (en) | L-acetyl carnitine and l-propionyl carnitine composition for the prevention and treatment of kidney dysfunctions and diseases | |
| JP3644024B2 (en) | Peritoneal dialysate | |
| WO2009123029A1 (en) | Blood ammonia level regulator | |
| JP2007529408A (en) | Use of alpha-ketoglutarate to treat malnutrition and high plasma glucose status | |
| PT1400246E (en) | Oral compositions for the treatment of obese, non-diabetic mammals, including humans | |
| Gokal | Peritoneal dialysis solutions: nutritional aspects | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040402 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040402 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040402 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080222 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120229 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120229 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130228 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140228 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |